Free Trial
CVE:RX

BioSyent (RX) Stock Price, News & Analysis

BioSyent logo
C$9.90 -0.90 (-8.33%)
As of 04/4/2025 03:55 PM Eastern

About BioSyent Stock (CVE:RX)

Key Stats

Today's Range
C$9.90
C$11.12
50-Day Range
C$9.90
C$11.36
52-Week Range
C$8.24
C$12.13
Volume
4,330 shs
Average Volume
4,163 shs
Market Capitalization
C$113.23 million
P/E Ratio
16.07
Dividend Yield
1.82%
Price Target
N/A
Consensus Rating
N/A

Company Overview

BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis. In addition, the company provides Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter; Combogesic to manage mild to moderate acute pain and reduction of fever in adults; and Proktis-M, a rectal suppository for the healing of the anus and rectum. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. BioSyent Inc. was founded in 2006 and is headquartered in Mississauga, Canada.

Remove Ads
Receive RX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioSyent and its competitors with MarketBeat's FREE daily newsletter.

RX Stock News Headlines

New “Trump” currency proposed in DC
According to one of the most connected men in Washington… A surprising new bill was just introduced in Washington. Its purpose: to put Donald Trump’s face on the $100 note. All to celebrate a new “golden age” for America.
BioSyent Inc. (RX.V)
Calculating The Fair Value Of BioSyent Inc. (CVE:RX)
BioSyent Inc. (BIOYF)
BioSyent Inc.
See More Headlines

RX Stock Analysis - Frequently Asked Questions

BioSyent's stock was trading at C$11.00 at the beginning of 2025. Since then, RX shares have decreased by 10.0% and is now trading at C$9.90.
View the best growth stocks for 2025 here
.

BioSyent Inc. (CVE:RX) announced its quarterly earnings results on Thursday, May, 25th. The company reported $0.06 EPS for the quarter, missing analysts' consensus estimates of $0.08 by $0.02. The firm earned $3.82 million during the quarter, compared to analysts' expectations of $4.80 million. BioSyent had a net margin of 20.60% and a trailing twelve-month return on equity of 20.01%.

Shares of RX stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

Based on aggregate information from My MarketBeat watchlists, some other companies that BioSyent investors own include Aurora Cannabis (ACB), Astec Industries (ASTE), Bank of Nova Scotia (BNS), Carnival Co. & (CCL), Cisco Systems (CSCO), Devon Energy (DVN) and Ford Motor (F).

Company Calendar

Last Earnings
5/25/2017
Today
4/04/2025

Industry, Sector and Symbol

Stock Exchange
CVE
Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Current Symbol
CVE:RX
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
18.05
Forward P/E Ratio
16.01
P/E Growth
N/A
Net Income
C$7.02 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$34.06 million
Cash Flow
C$3.62 per share
Price / Cash Flow
3.07
Book Value
C$3.22 per share
Price / Book
3.45

Miscellaneous

Free Float
N/A
Market Cap
C$127.18 million
Optionable
Not Optionable
Beta
0.93
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (CVE:RX) was last updated on 4/5/2025 by MarketBeat.com Staff
From Our Partners